Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,United States ,Massachusetts ,Americans ,Alison Schecter ,Jason Fredette ,Charvy Narain ,Betty Raman ,Oxford University Radcliffe Department Of Medicine ,Oxford University Innovation ,Radcliffe Department Of Medicine ,World University Rankings ,University Of Oxford ,Oxford University ,Oxford University Radcliffe Department ,Long Covid ,British Heart Foundation Oxford Centre ,Radcliffe Department ,Times Higher Education ,Axcella Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Business Wire ,Coronavirus Pandemic ,Technology ,Science ,Business ,Health ,Biotechnology ,Oxford ,Clinical Trials ,Europe ,